ONL Therapeutics, Inc., an Ann Arbor, Mich.-based biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, closed on $46.9m in a Series B financing round.
The round included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that participated in the round include ONL Therapeutics management, InFocus Capital Partners, ExSight Ventures, the University of Michigan’s Michigan Investment in New Technology Startups (MINTS) program, Western Michigan University’s Biosciences Research & Commercialization Center, and the Capital Community Angels.
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months
December 22, 2020 07:00 ET | Source: ONL Therapeutics ONL Therapeutics Ann Arbor, Michigan, UNITED STATES
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it closed on $46.9 million in a Series B Preferred Stock financing round. The financing included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that participated in the round includ